Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01477073
Other study ID # GEXGP24102
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 2011
Est. completion date May 2012

Study information

Verified date May 2021
Source Glycotope GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the current study is the pharmacokinetic and pharmacodynamic characterization of a multiple dose administration of FSH-GEX™ in healthy pituitary-suppressed female volunteers, in comparison with two marketed comparator products or placebo.


Description:

Healthy pituitary-suppressed female subjects received multiple doses of FSH-GEX at one of 2 different dose levels (75 IU and 150 IU dosing once daily (QD), or 150 IU (dosing once every other day (QAD)) for maximal 7 Days. They were compared with subjects who received a urinary FSH or a recombinant FSH or placebo.


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date May 2012
Est. primary completion date April 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: 1. Female subjects from 18-40 years of age at screening. 2. Subjects must be in good health as determined by medical and gynecological history, physical and gynecological examination, vital signs, body measurements, electrocardiogram, and laboratory tests 3. Subjects must be willing to use additional non-hormonal contraception 4. Subjects must have used a combined oral contraceptive, combined contraceptive vaginal ring or combined contraceptive patch 5. Vital signs which are within the following ranges: systolic blood pressure between 90-140 mmHg, diastolic blood pressure between 50-90 mmHg, pulse rate between 40 - 100 bpm 6. Subjects must have a body weight of minimally 50.0 kg with a BMI between 18.0 and 29.9 kg/m2 7. Able to provide written informed consent prior to study participation. 8. Able to communicate well with the investigator and to understand and comply with the requirements of the study. Exclusion Criteria: 1. Smokers of more than 5 cigarettes per day. 2. Average daily intake of more than 3 units of alcohol per day (where 1 unit equals 250 mL of beer, 125 mL of wine or 25 mL of spirits) or an average weekly intake of more than 21 units alcohol. 3. Use of any prescription drug or over-the-counter medication from screening until the end-of-study visit, without prior approval of the investigator. Paracetamol® is acceptable without prior approval. 4. Any drugs that may reduce the effectiveness of combination oral contraceptive (COC) from screening until the end-of-study visit 5. Administration of any investigational product or use of any investigational device within 30 days prior to Screening. 6. Donation or loss of 500 mL or more of blood within 90 days prior to first dosing of FSH-GEX(TM). 7. History of acute or chronic bronchospastic disease 8. History of allergies for drugs, seafood, nuts, eggs, wasp-stings; history of atopic allergy. A known hypersensitivity to any of the study drugs. 9. Any surgical or medical condition which might alter the absorption, distribution, metabolism, or excretion of drugs or which may jeopardize the subject in case of participation in the study. 10. History or presence of any malignancy. 11. Determined or suspected pregnancy. 12. Breast feeding women. 13. History of (or current) endocrine abnormalities 14. Contraindication for the use of oral contraceptives 15. Contraindication for the use of follitropin alfa, follicle-stimulating hormone (FSH) or any of the excipients (hypersensitivity to follitropin alfa, FSH or any of the excipients; tumors of the hypothalamus or the pituitary gland; ovarian enlargement or cyst not due to polycystic ovarian disease; gynecological bleeding of unknown origin; ovarian, uterine, or mammary carcinoma). 16. Porphyria or family history of porphyria. 17. History of ovarian surgery. 18. Any ovarian or abdominal abnormality that would interfere with adequate ultrasound investigation. 19. An abnormal cervical smear 20. History or presence of an immune-compromising disease, or a positive human immunodeficiency virus (HIV) test result in the past or at the screening visit. 21. History of Hepatitis B or C, or a positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result at the screening visit. 22. History of drug or alcohol abuse within the 12 months prior to the screening visit or evidence of such abuse 23. Planned surgery or hospitalization during the period of the study. 24. Concurrent participation or participation within 30 days before screening in another clinical trial, or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study or previous participation in the 104676-CS0160 (FSH-GEXTM) study. 25. Injection of one or more doses of any depot contraceptive drug /drug combination =10 months prior to screening.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FSH-GEX™

recombinant FSH

urinary FSH

Placebo


Locations

Country Name City State
Netherlands Glycotope Investigational Site Groningen

Sponsors (2)

Lead Sponsor Collaborator
Glycotope GmbH Glycotope Biotechnology GmbH

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Abd-Elaziz K, Duijkers I, Stöckl L, Dietrich B, Klipping C, Eckert K, Goletz S. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials. Hum Reprod. 2017 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary safety and tolerability of FSH-GEX™ following multiple dose administration by subcutaneous injection frequency of dose related adverse events, measurement of vital signs, body measurements, transvaginal ultrasound, ECG and laboratory values in comparison to placebo and the two comparators with marketing authorization 43 days
Secondary pharmacokinetic profile of FSH-GEX™ following multiple dose administration by subcutaneous injection (part 1) Peak Plasma Concentration (Cmax) 28 time points up to 14 days post-dose
Secondary pharmacokinetic profile of FSH-GEX™ following multiple dose administration by subcutaneous injection (part 2) Area under the plasma concentration versus time curve (AUC) 28 time points up to 14 days post-dose
Secondary pharmacodynamic parameters of FSH-GEX™ following multiple dose administration by subcutaneous injection Estradiol (E2), Luteinizing Hormone (LH) and inhibin B serum levels 17 time points up to 14 days post-dose
Secondary pharmacodynamic parameters of FSH-GEX™ following multiple dose administration by subcutaneous injection follicular response and endometrial thickness as determined by transvaginal ultrasonography 9 time points up to14 days post-dose
See also
  Status Clinical Trial Phase
Completed NCT06239051 - Greening the Humanitas Fertility Center: How to Build a More Sustainable Medical Daily Routine
Recruiting NCT05179993 - Detection of Microplastics in Human Granulosa Cells and in the Follicular Fluid of Women Undergoing ICSI Treatment
Recruiting NCT03767569 - Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients Phase 3
Completed NCT03737253 - Hormone Evaluation in Artificial Reproductive Technology Phase 4
Not yet recruiting NCT02237755 - Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response. Phase 2/Phase 3
Not yet recruiting NCT02237781 - Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins Phase 2/Phase 3
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Recruiting NCT06098495 - Looking for a Blood Epigenetic Signature to Predict Female Infertility
Completed NCT03998553 - Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women N/A
Completed NCT05189145 - Hormonal Monitoring and Progesterone Adjustment in Frozen Embryo Transfer Cycles N/A
Recruiting NCT05050747 - Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle
Completed NCT01620346 - Intracytoplasmic Morphologically Selected Sperm Injection and Advanced Maternal Age N/A
Completed NCT00315029 - Patient-Centered Implementation Trial for Single Embryo Transfer N/A
Recruiting NCT03080584 - Effect of 12 Weeks of Acupuncture on AMH and COH in Low Responder Patients N/A
Not yet recruiting NCT05106712 - Vitamin D Supplementation and Improvement of PCOS Therapy and IVF Outcomes in Infertile Saudi Women N/A
Recruiting NCT06041204 - Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism N/A
Completed NCT01604044 - Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial. Phase 1
Completed NCT02328924 - There is a Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome in Antagonist Protocols? Phase 4
Completed NCT04019899 - Myo-inositol and Vitamin D3 During IVF N/A
Completed NCT02454829 - Follow-up of Ovarian Function in Young Women Who Underwent Ovarian Cortex Cryopreservation N/A